BioAge Labs, Inc. (BIOA) has a consensus analyst rating of Buy, based on 3 analysts covering the stock. Of those, 2 recommend buying, 1 recommend holding, and 0 recommend selling.
The analyst consensus price target for BIOA is $42.50, representing a +156.5% upside from the current price of $16.57. Price targets range from a low of $23.00 to a high of $62.00.
